{"id":951577,"date":"2026-04-15T09:02:47","date_gmt":"2026-04-15T13:02:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/"},"modified":"2026-04-15T09:02:47","modified_gmt":"2026-04-15T13:02:47","slug":"immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/","title":{"rendered":"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <b><br \/>\n          <b>SYDNEY, AUSTRALIA, April  15, 2026  (GLOBE NEWSWIRE) &#8212; <\/b><br \/>\n        <\/b><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GSK04NR_Mt-CJ34hDAKxT8BpHpRdXxhYF7bTmbMYhY-urAt3z1Ufj94ymLzlMI2ANKtTsbbO80sil8xEN_4yAA==\" rel=\"nofollow\" target=\"_blank\">Immutep Limited<\/a> (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (\u201cefti\u201d) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need.<\/p>\n<p align=\"justify\">The FDA\u2019s Orphan Drug Designation program is designed to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States. Benefits of ODD may include regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval.<\/p>\n<p align=\"justify\">This designation recognises the potential therapeutic relevance of efti in STS, supported by encouraging clinical data from the investigator-initiated Phase II EFTISARC-NEO trial which has been evaluating efti in combination with radiotherapy and KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) in the neoadjuvant setting in patients with resectable soft tissue sarcoma. In 38 evaluable patients, the study met its primary endpoint, demonstrating a median tumour hyalinization\/fibrosis of 51.5%, significantly exceeding the pre-specified target of 35% and historical benchmarks of ~15% with radiotherapy alone.<sup>1<\/sup><\/p>\n<p align=\"justify\">These results were observed across multiple sarcoma subtypes and were supported by translational data showing immune activation consistent with efti\u2019s mechanism of action, with a favourable safety profile and no delays to planned surgery.<sup>2<\/sup><\/p>\n<p align=\"justify\">\n        <b>CEO of Immutep, Marc Voigt said:<\/b> \u201cWe are pleased that the FDA has recognised the potential of efti for patients with soft tissue sarcoma, a rare and difficult to treat cancer. As previously communicated, the Company is currently undertaking a comprehensive review and analysis following the discontinuation of its Phase III TACTI-004 trial and the outcome will influence the decision regarding any potential future clinical trial with efti. The FDA\u2019s designation, based on very encouraging data from the EFTISARC-NEO trial, provides us with a potential direct step forward into a late-stage study in the neoadjuvant setting for STS.\u201d<\/p>\n<p align=\"justify\">\n        <b>About Immutep<\/b><br \/>\n        <br \/>Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases<i>.<\/i> The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3\u2019s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NehzkcGWxeZn1EyqFz4WoJ6Ef7gBJ_Iun5FViWtvdj-HrtSFDXLcPFA1_lv3BV6tMYJXWgnHV2ozA_D3OajzOg==\" rel=\"nofollow\" target=\"_blank\">www.immutep.com<\/a>.<\/p>\n<p align=\"justify\">1. ESMO Congress 2025 Proffered Paper presentation, \u201cEFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma\u201d.<br \/>2. CTOS 2025 Annual Meeting Oral Presentation, \u201cPrimary endpoint and translational correlates from EFTISARC-NEO: Phase II trial of neoadjuvant eftilagimod alfa (efti), pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma\u201d.<\/p>\n<p align=\"justify\">KEYTRUDA<sup>\u00ae<\/sup> is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.<\/p>\n<p align=\"justify\">\n        <b>Australian Investors\/Media:<\/b><br \/>\n        <br \/>Eleanor Pearson, Sodali &amp; Co.<br \/>+61 2 9066 4071; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7hbFphmzdMVZfOzPExTZBTh7CRIEjo3rvnjOgpreECC2XlfbNfMpzXgYRoh6h1XqwS5_Jc-43DVDyXOf9tS6cJW41F4AFJJapu6hJ5tUztrPtqMFOGt8V2OqrbyZv9wH\" rel=\"nofollow\" target=\"_blank\">eleanor.pearson@sodali.com<\/a><\/p>\n<p align=\"justify\">\n        <b>U.S. Investors\/Media: <\/b><br \/>\n        <br \/>Matthew Beck, astr partners <br \/>Ph: +1 (917) 415-1750; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AXOB66oLS-KYIlPNlP23DsUfgxo7DDg4iLl-kmkLcYgUQCxEWHsAw2plfv5lT65BQv6G30MN0fJL0dw7qxEpKr21B8FoBa3jqnn21tQZUrg_WDZQd0YCtSD2y68yE-1D\" rel=\"nofollow\" target=\"_blank\">matthew.beck@astrpartners.com<\/a><\/p>\n<p>This announcement was authorised for release by the CEO of Immutep Limited.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2JiODc3N2ItYzM0NC00ODk5LWJjMWYtOWI4ZWNlZGJjYzgxLTEwMzE0MDUtMjAyNi0wNC0xNS1lbg==\/tiny\/Immutep-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (\u201cefti\u201d) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need. The FDA\u2019s Orphan Drug Designation program is designed to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States. Benefits of ODD may include regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval. This designation recognises the potential therapeutic relevance of efti in STS, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-951577","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (\u201cefti\u201d) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need. The FDA\u2019s Orphan Drug Designation program is designed to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States. Benefits of ODD may include regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval. This designation recognises the potential therapeutic relevance of efti in STS, &hellip; Continue reading &quot;Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T13:02:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma\",\"datePublished\":\"2026-04-15T13:02:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/\"},\"wordCount\":522,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/\",\"name\":\"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM=\",\"datePublished\":\"2026-04-15T13:02:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/","og_locale":"en_US","og_type":"article","og_title":"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma - Market Newsdesk","og_description":"SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (\u201cefti\u201d) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need. The FDA\u2019s Orphan Drug Designation program is designed to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States. Benefits of ODD may include regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval. This designation recognises the potential therapeutic relevance of efti in STS, &hellip; Continue reading \"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-15T13:02:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma","datePublished":"2026-04-15T13:02:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/"},"wordCount":522,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/","name":"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM=","datePublished":"2026-04-15T13:02:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDA4MSM3NTM2NDI0IzIwMTk4MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/951577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=951577"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/951577\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=951577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=951577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=951577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}